ACCESS DB # 174821

FOR OFFICIAL USE ONLY

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARK BERCH Examiner # : 59193 Date: 8/12/21

Art Unit: 1624 Phone Number: 2-0663 Serial Number: 10518246

Location (Bldg/Room#): 5C01 (Mailbox #): 5C18 Results Format Preferred (circle): (PAPER) DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



RN= 253124-46-8

Just this exact cmpd

****

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

_____ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

____In-house sequence systems

___Commercial ___Oligomer ____Score/Length

___ Interference ___ SPDI ____ Encode/Transl

_____ Other (specify)

=> d ibib abs hitstr l9 1-18

L9 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:523302 HCAPLUS
DOCUMENT NUMBER: 143:38434
TITLE: Use of adenosine derivatives for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, NIDDM
INVENTOR(S): Bountra, Charanjit; Hyafil, Francois; Kirilovsky, Jorge Eduardo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053712	A1	20050616	WO 2004-EP13659	20041130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-526491P P 20031202
OTHER SOURCE(S): MARPAT 143:38434
GI



I

AB Use of adenosine derivs. of formula I (e.g., (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol) is claimed in the treatment of dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome and NIDDM.

IT **253124-46-8 253124-46-8D**, salts and solvates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of adenosine derivs. for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, NIDDM)
RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:534219 HCAPLUS
DOCUMENT NUMBER: 141:94304

TITLE: Heterocyclic-substituted adenosine derivative in polymorph III form for use in therapy
INVENTOR(S): Freer, Richard; Saklatvala, Paula; Shipton, Mark Ralph
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055034	A1	20040701	WO 2003-EP14489	20031216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-434463P P 20021218

AB The present invention relates to a heterocyclic substituted adenosine derivative, i.e. (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form III, pharmaceutical formulations thereof and their use in therapy for ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, and sleep apnea, etc.

IT **253124-46-8P**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(heterocyclic-substituted adenosine derivative in polymorph III form for use in therapy)

RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:534218 HCAPLUS
DOCUMENT NUMBER: 141:94303
TITLE: Heterocyclyl substituted adenosine derivative in polymorph IV form
INVENTOR(S): Varlashkin, Peter Gregory
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055033	A1	20040701	WO 2003-EP14516	20031216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-434515P P 20021218

AB The present invention relates to a heterocyclic substituted adenosine derivs., i.e. (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form IV, pharmaceutical formulations thereof and their use in therapy for ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, and sleep apnea, etc.

IT **253124-46-8**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(heterocyclic substituted adenosine derivative in polymorph IV form for use

in therapy)
RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:534217 HCAPLUS
DOCUMENT NUMBER: 141:94302
TITLE: Adenosine derivative in polymorph V form
INVENTOR(S): Freer, Richard; Roberts, John Charles; Shipton, Mark Ralph
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055032	A1	20040701	WO 2003-EP14508	20031216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-434464P P 20021218

AB The present invention relates to heterocyclyl substituted adenosine derivative, i.e. (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form V, pharmaceutical formulations thereof and their use in

therapy for ischemic heart disease, peripheral vascular disease, stroke, pain, migraine, CNS disorder, and sleep apnea, etc.

IT **253124-46-8P**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(heterocyclyl substituted adenosine derivative in polymorph V form for use in therapy)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:1006999 HCAPLUS
DOCUMENT NUMBER: 140:28026
TITLE: Process for the preparation and crystallization of polymorph heterocyclyl substituted adenosine derivative
INVENTOR(S): Shipton, Mark Ralph; Smith, Neil Michael; Whitehead, Andrew Jonathan; Wood-Kaczmar, Marian Wladyslaw
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106475	A2	20031224	WO 2003-EP6412	20030616
WO 2003106475	A3	20040304		
WO 2003106475	C1	20050217		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1513858	A2	20050316	EP 2003-740271 20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005533792	T2	20051110	JP 2004-513306 20030616
US 2005222178	A1	20051006	US 2004-518246 20041216
PRIORITY APPLN. INFO.:			US 2002-388765P P 20020617
			WO 2003-EP6412 W 20030616

OTHER SOURCE(S): CASREACT 140:28026

AB The present invention relates to an improved process for the preparation of polymorph heterocyclyl substituted adenosine derivs. More particularly the invention is concerned with preparation of particular phys. forms of (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluoro-phenylamino)-9H-purin-9-yl]-tetrahydro-furan-3,4-diol.

IT **253124-46-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(process for the preparation and purification of polymorph heterocyclyl substituted adenosine derivative)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2002:977835 HCAPLUS
DOCUMENT NUMBER:	138:44673
TITLE:	Adenosine derivative in Polymorph II form
INVENTOR(S):	King, Paula
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK
SOURCE:	PCT Int. Appl., 12 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102822	A1	20021227	WO 2002-GB2841	20020619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1397378	A1	20040317	EP 2002-735635	20020619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005511488	T2	20050428	JP 2003-506294	20020619
US 2004180908	A1	20040916	US 2003-481612	20031219
PRIORITY APPLN. INFO.:			GB 2001-15178	A 20010620
			WO 2002-GB2841	W 20020619

OTHER SOURCE(S): MARPAT 138:44673

AB Preparation of a polymorphic form (Polymorph II) of adenosine derivative (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenyl-amino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol (I) by crystallization from Me iso-Bu ketone by heating is described. A pharmaceutical formulation containing I polymorph is useful in decreasing plasma free fatty acid concentration, reducing heart rate, or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnea. Polymorph I was characterized by X-ray powder diffraction and Raman spectra.

IT **253124-46-8**
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(preparation of polymorphic form II of adenosine derivative for therapeutic uses)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:977834 HCAPLUS
DOCUMENT NUMBER: 138:44672
TITLE: Adenosine derivative in Polymorph I form
INVENTOR(S): King, Paula; Sickles, Barry Riddle
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102821	A1	20021227	WO 2002-GB2814	20020619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1397379	A1	20040317	EP 2002-740888	20020619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500302	T2	20050106	JP 2003-506293	20020619
US 2004162297	A1	20040819	US 2003-481291	20031219
PRIORITY APPLN. INFO.:			GB 2001-15178	A 20010620
			WO 2002-GB2814	W 20020619

AB Preparation of a polymorphic form (Polymorph I) of adenosine derivative (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenyl-amino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol (I) by crystallization from DMF by heating is described. A pharmaceutical formulation containing I polymorph is useful in decreasing plasma free fatty acid concentration, reducing

heart rate, or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnea. Polymorph I was characterized by X-ray powder diffraction and Raman spectra.

IT **253124-46-8**
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(preparation of polymorphic form I of adenosine derivative for therapeutic uses)

RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:977670 HCAPLUS
DOCUMENT NUMBER: 138:49946
TITLE: Use of adenosine A1 receptor agonists for the treatment of nociceptive pain
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Collins, Susanne Denise
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102392	A1	20021227	WO 2002-GB2817	20020619

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 2001-15182 A 20010620
OTHER SOURCE(S): MARPAT 138:49946
AB The invention discloses the use of adenosine derivs. in the treatment of nociceptive pain. The adenosine derivs of the invention include e.g. (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol.
IT **253124-46-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A1 receptor agonists for treatment of nociceptive pain)
RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:736265 HCAPLUS
DOCUMENT NUMBER: 137:232865
TITLE: Process for preparing N6-substituted aminopurine ribofuranose nucleosides via condensation reaction of halopurine with chlorofluoroaniline
INVENTOR(S): Berry, Malcolm; Roberts, John C.; Xie, Shiping
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074781	A1	20020926	WO 2002-GB1344	20020319

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1370569	A1	20031217	EP 2002-718299	20020319
EP 1370569	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534003	T2	20041111	JP 2002-573790	20020319
US 2005176949	A1	20050811	US 2003-471682	20020319
AT 303396	E	20050915	AT 2002-718299	20020319
PRIORITY APPLN. INFO.:			GB 2001-6867 A	20010320
			WO 2002-GB1344 W	20020319

OTHER SOURCE(S): CASREACT 137:232865; MARPAT 137:232865

AB An improved process for preparing N6-substituted aminopurine ribofuranose nucleosides. Compds. of this type are known to be useful in the preparation of compds. having activity at adenosine receptors, e.g., Adenosine A1 receptor (no data). The process comprises the step of condensation reaction of 6-halopurine ribofuranose nucleoside with an amine in the presence of CaCO3, wherein acid is added to the reaction mixture Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in 74% yield by condensation of 9-[(3aR,4R,6S,6aS)-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2,2-dimethyltetrahydrofuro(3,4-d[1,3]dioxol-4-yl)]-6-chloro-9H-purine with 4-chloro-2-fluoroaniline.

IT **253124-46-8P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing N6-substituted aminopurine ribofuranose nucleosides via condensation reaction of halopurine with chlorofluoroaniline)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:695793 HCAPLUS
DOCUMENT NUMBER: 137:210974
TITLE: Treatment of emesis with adenosine A1 receptor agonists
INVENTOR(S): Bountra, Charanjit; Dale, Timothy James; Gardner, Christopher John; Reeves, Julian James; Sheehan, Michael John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002069982	A1	20020912	WO 2002-GB1025		20020306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1397147	A1	20040317	EP 2002-702549		20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004522788	T2	20040729	JP 2002-569157		20020306
US 2004167092	A1	20040826	US 2004-469792		20040329
PRIORITY APPLN. INFO.:			GB 2001-5469	A	20010306
			WO 2002-GB1025	W	20020306

OTHER SOURCE(S): MARPAT 137:210974

AB The present invention relates to the use of adenosine A1 agonists having an agonist action at adenosine A1 receptors in the treatment of emesis.

IT **253124-46-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of emesis with adenosine A1 receptor agonists)

RN 253124-46-8 HCAPLUS
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472502 HCAPLUS
DOCUMENT NUMBER: 135:66249
TITLE: Formulations of adenosine A1 receptor agonists as analgesics
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045715	A2	20010628	WO 2000-GB4885	20001219
WO 2001045715	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1248632	A2	20021016	EP 2000-985629	20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518068	T2	20030603	JP 2001-546654	20001219
US 2003004126	A1	20030102	US 2002-168189	20020618
PRIORITY APPLN. INFO.:			GB 1999-30071	A 19991220
			WO 2000-GB4885	W 20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal, an adenosine A1 agonist or a physiol. acceptable salt or a solvate and an opioid. The present invention also provides pharmaceutical formulations and patient

packs comprising the combinations. 5'-Deoxy-5'-fluoro-N-(tetrahydropyran-4-yl)adenosine and administered orally to rats and morphine was administered s.c. to the same rats. The compds. inhibited carrageenan-induced edema and allodynia.

IT **253124-46-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 receptor agonists as analgesics)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:472501 HCAPLUS
DOCUMENT NUMBER: 135:66248
TITLE: Formulations of adenosine A1 receptor agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045714	A2	20010628	WO 2000-GB4892	20001219
WO 2001045714	A3	20020228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1239881	A2	20020918	EP 2000-985633		20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003518067	T2	20030603	JP 2001-546653		20001219
US 2003004129	A1	20030102	US 2002-168242		20020618
PRIORITY APPLN. INFO.:			GB 1999-30083	A	19991220
			WO 2000-GB4892	W	20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated comprises administering to a mammal an adenosine A1 agonist or a physiol. acceptable salt or solvate and gabapentin or pregabalin. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection.

IT **253124-46-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 receptor agonists)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2001:472474 HCAPLUS
DOCUMENT NUMBER:	135:81974
TITLE:	Formulations of adenosine A1 agonists
INVENTOR(S):	Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK
SOURCE:	PCT Int. Appl., 26 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045686	A2	20010628	WO 2000-GB4970	20001219
WO 2001045686	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001022083	A5	20010703	AU 2001-22083	20001219
EP 1239883	A2	20020918	EP 2000-985682	20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518044	T2	20030603	JP 2001-546425	20001219
US 2002198170	A1	20021226	US 2002-168283	20020618
PRIORITY APPLN. INFO.:			GB 1999-30082 A	19991220
			WO 2000-GB4970 W	20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and an EP1 antagonist. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection.

IT **253124-46-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 agonists)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472473 HCAPLUS
DOCUMENT NUMBER: 135:81973
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045685	A2	20010628	WO 2000-GB4902	20001219
WO 2001045685	A3	20020228		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1239882	A2	20020918	EP 2000-985643	20001219
EP 1239882	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518043	T2	20030603	JP 2001-546424	20001219
AT 277639	E	20041015	AT 2000-985643	20001219
US 2003018008	A1	20030123	US 2002-168190	20020618
PRIORITY APPLN. INFO.:			GB 1999-30077 A	19991220
			WO 2000-GB4902 W	20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and a 5HT3 antagonist. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-

[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol (adenosine A1 agonist) (I) was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection. Alosetron and I inhibited carrageenan-induced edema and allodynia in rats.

IT **253124-46-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 agonists)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:472472 HCAPLUS
DOCUMENT NUMBER: 135:81972
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045684	A2	20010628	WO 2000-GB4888	20001219
WO 2001045684	A3	20020314		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1239880	A2	20020918	EP 2000-985631	20001219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518042	T2	20030603	JP 2001-546423	20001219
US 2003008842	A1	20030109	US 2002-168196	20020618
PRIORITY APPLN. INFO.:			GB 1999-30079	A 19991220
			WO 2000-GB4888	W 20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and a sodium channel blocker. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection.

IT **253124-46-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 agonists)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472471 HCAPLUS
DOCUMENT NUMBER: 135:81971
TITLE: Formulations of adenosine A1 agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045683	A2	20010628	WO 2000-GB4883	20001219
WO 2001045683	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1239879	A2	20020918	EP 2000-985627	20001219
EP 1239879	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519104	T2	20030617	JP 2001-546422	20001219
AT 260119	E	20040315	AT 2000-985627	20001219
US 2003004128	A1	20030102	US 2002-168195	20020618

PRIORITY APPLN. INFO.: GB 1999-30075 A 19991220
WO 2000-GB4883 W 20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with it comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and an NSAID, e.g., a COX-2 inhibitor. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol (I) was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection. I and 2-(4-ethoxy-phenyl)-3-(4-methanesulfonylphenyl)pyrazolo[1,5-b]pyridazine(COX-2 inhibitor), were administered at 1% to rats. The compds. showed inhibition of carrageenan-induced edema and allodynia.

IT **253124-46-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 agonists)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:472470 HCAPLUS
DOCUMENT NUMBER: 135:66244
TITLE: Formulations of adenosine A1 receptor agonists
INVENTOR(S): Bountra, Charanjit; Clayton, Nicholas Maughan; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045682	A2	20010628	WO 2000-GB4878	20001219
WO 2001045682	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1239878	A2	20020918	EP 2000-985623	20001219
EP 1239878	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518041	T2	20030603	JP 2001-546421	20001219
AT 260118	E	20040315	AT 2000-985623	20001219
US 2003004127	A1	20030102	US 2002-168193	20020618
PRIORITY APPLN. INFO.:			GB 1999-30085 A	19991220
			WO 2000-GB4878 W	20001219

AB A method of treating conditions associated with pain and alleviating the symptoms associated with them comprises administering to a mammal an adenosine A1 agonist or a salt or solvate and a 5HT1 receptor agonist. The present invention also provides pharmaceutical formulations and patient packs comprising the combinations. Thus, (2S,3S,4R,5R)-2-(5-tert-

butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)purin-9-yl]tetrahydrofuran-3,4-diol was prepared in a series of steps by the reaction of (3aS,4S,6R,6aR)-6-(6-chloropurin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid with 2,2-dimethylpropionic acid hydrazide followed by the cyclization of the resulting compound, and subsequent treatment with 4-chloro-2-fluoroaniline and deprotection.

IT **253124-46-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(formulations of adenosine A1 receptor agonists)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:819388 HCAPLUS

DOCUMENT NUMBER: 132:64480

TITLE: Preparation of adenosine derivatives as antiinflammatory agents

INVENTOR(S): Bays, David Edmund; Cousins, Richard Peter Charles; Dyke, Hazel Joan; Eldred, Colin David; Judkins, Brian David; Pass, Martin; Pennell, Andrew Michael Kenneth

PATENT ASSIGNEE(S): Glaxo Group Ltd., UK

SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967262	A1	19991229	WO 1999-EP4182	19990621

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2335520	AA	19991229	CA 1999-2335520		19990621
AU 9945146	A1	20000110	AU 1999-45146		19990621
AU 758018	B2	20030313			
BR 9911498	A	20010320	BR 1999-11498		19990621
EP 1090019	A1	20010411	EP 1999-927999		19990621
EP 1090019	B1	20040929			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200100449	T2	20010821	TR 2001-200100449		19990621
EE 200000784	A	20020415	EE 2000-784		19990621
JP 2002518509	T2	20020625	JP 2000-555913		19990621
JP 3378240	B2	20030217			
JP 2003040891	A2	20030213	JP 2002-170486		19990621
NZ 508915	A	20030926	NZ 1999-508915		19990621
EP 1447407	A1	20040818	EP 2004-76465		19990621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
AT 277941	E	20041015	AT 1999-927999		19990621
PT 1090019	T	20050131	PT 1999-927999		19990621
ES 2226399	T3	20050316	ES 1999-927999		19990621
TW 541312	B	20030711	TW 1999-88111178		19990701
ZA 2000007514	A	20020123	ZA 2000-7514		20001214
NO 2000006520	A	20010214	NO 2000-6520		20001220
NO 318788	B1	20050509			
HR 2000000896	A1	20011231	HR 2000-896		20001221
BG 105155	A	20010928	BG 2001-105155		20010115
US 6492348	B1	20021210	US 2001-736018		20010306
HK 1034978	A1	20050408	HK 2001-105686		20010814
US 2003096788	A1	20030522	US 2002-217107		20020813
US 6677316	B2	20040113			
PRIORITY APPLN. INFO.:			GB 1998-13554	A	19980623
			EP 1999-927999	A3	19990621
			JP 2000-555913	A3	19990621
			WO 1999-EP4182	W	19990621
			US 2001-736018	A1	20010306

OTHER SOURCE(S): MARPAT 132:64480

GI



I

AB Adenosine derivs. I (X = O, CH2; Y and Z = O, N, CH, alkylamine; W = heteroatom; R1 = H, alkylcycloalkyl, heterocycle, fused bicyclic, substituted phenyl) which is an agonist at the adenosine A1 and A3 receptors. Thus, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5[6-(tetrahydropyran-4-ylamino)-purin-9-yl]tetrahydrofuran-3,4-diol was prepared as adenosine A1 and A3 receptors (ECR are resp. 4.16 and 152).

IT **253124-46-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of adenosine derivs. as antiinflammatory agents)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his ful

     (FILE 'HOME' ENTERED AT 17:08:28 ON 27 DEC 2005)

     FILE 'HCAPLUS' ENTERED AT 17:08:36 ON 27 DEC 2005
                 E SHIPTON MARK/AU
L1            33 SEA ABB=ON  ("SHIPTON M H"/AU OR "SHIPTON M R"/AU OR "SHIPTON
                   MARK"/AU OR "SHIPTON MARK H"/AU OR "SHIPTON MARK HENRY"/AU OR
                   "SHIPTON MARK R"/AU OR "SHIPTON MARK RALPH"/AU)
                   E SMITH NEIL MICHAEL/AU
L2            12 SEA ABB=ON  ("SMITH NEIL M"/AU OR "SMITH NEIL MICHAEL"/AU)
                   E WHITEHEAD ANDREW JONATHAN/AU
L3            32 SEA ABB=ON  ("WHITEHEAD ANDREW J"/AU OR "WHITEHEAD ANDREW
                   JOHN"/AU OR "WHITEHEAD ANDREW JONATHAN"/AU)
                   E WOOD KACZMAR MARIAN/AU
L4             8 SEA ABB=ON  ("WOOD KACZMAR M"/AU OR "WOOD KACZMAR M W"/AU OR
                   "WOOD KACZMAR MARIAN"/AU OR "WOOD KACZMAR MARIAN WLADYLAW"/AU
                   OR "WOOD KACZMAR MARIAN WLADYSLAW"/AU)
L5             1 SEA ABB=ON  L1 AND L2 AND L3 AND L4
                   D TI
                   SELECT RN L5 1-1

     FILE 'REGISTRY' ENTERED AT 17:10:10 ON 27 DEC 2005
L6             2 SEA ABB=ON  (253124-46-8/BI OR 253127-02-5/BI)

     FILE 'HCAPLUS' ENTERED AT 17:10:16 ON 27 DEC 2005
L7             1 SEA ABB=ON  L5 AND L6

     FILE 'REGISTRY' ENTERED AT 17:12:20 ON 27 DEC 2005
L8             1 SEA ABB=ON  253124-46-8/RN  located via inventor search (above);
                                             display of compd & " " attached

     FILE 'HCAPLUS' ENTERED AT 17:12:44 ON 27 DEC 2005
L9            18 SEA ABB=ON  L8  18 cits from CA Plus

     FILE HOME

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 27 Dec 2005  VOL 144 ISS 1
     FILE LAST UPDATED: 26 Dec 2005  (20051226/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.
```

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d l8 1-1

- located via inventor search, attached.

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **253124-46-8** REGISTRY
ED Entered STN: 19 Jan 2000
CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H21 Cl F N7 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, PROUSDDR, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 19 Jan 2000

```
=> d que stat l9
L8            1 SEA FILE=REGISTRY ABB=ON  253124-46-8/RN
L9           18 SEA FILE=HCAPLUS ABB=ON  L8

=> d ibib abs hitstr l7 1-1
```

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1006999 HCAPLUS
DOCUMENT NUMBER: 140:28026
TITLE: Process for the preparation and crystallization of polymorph heterocyclyl substituted adenosine derivative
INVENTOR(S): **Shipton, Mark Ralph; Smith, Neil Michael; Whitehead, Andrew Jonathan; Wood-Kaczmar, Marian Wladyslaw**
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106475	A2	20031224	WO 2003-EP6412	20030616
WO 2003106475	A3	20040304		
WO 2003106475	C1	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1513858	A2	20050316	EP 2003-740271	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533792	T2	20051110	JP 2004-513306	20030616
US 2005222178	A1	20051006	US 2004-518246	20041216
PRIORITY APPLN. INFO.:			US 2002-388765P P	20020617
			WO 2003-EP6412 W	20030616

OTHER SOURCE(S): CASREACT 140:28026

AB The present invention relates to an improved process for the preparation of polymorph heterocyclyl substituted adenosine derivs. More particularly the invention is concerned with preparation of particular phys. forms of (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluoro-phenylamino)-9H-purin-9-yl]-tetrahydro-furan-3,4-diol.

IT **253124-46-8P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(process for the preparation and purification of polymorph heterocyclyl substituted adenosine derivative)

RN 253124-46-8 HCAPLUS

CN 3,4-Furandiol, 2-[6-[(4-chloro-2-fluorophenyl)amino]-9H-purin-9-yl]-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **253127-02-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the preparation and purification of polymorph heterocyclyl substituted adenosine derivative)
RN 253127-02-5 HCAPLUS
CN 9H-Purin-6-amine, N-(4-chloro-2-fluorophenyl)-9-[(3aR,4R,6S,6aS)-6-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]tetrahydro-2,2-dimethylfuro[3,4-d]-1,3-dioxol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.